Media, News
Prescient Therapeutics appoints accomplished medical professional Dr Gavin Shepherd as a director
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF), a clinical-stage oncology company developing personalised therapies for cancer, has appointed accomplished medical professional Dr Gavin Shepherd as an independent…
Media, News
Prescient Therapeutics: Current Developments in Cancer Treatment
Prescient Therapeutics, an ASX-listed company, is engaged in the development of drugs targeting various forms of cancer, with a specific focus on blood cancers that…
Article, Media, News
Prescient Therapeutics PTX-100 shows promising results in Phase 1b study
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) CEO and managing director Steven Yatomi-Clarke sits down with Jonathan Jackson in the Proactive studio ahead of a presentation of the…
Article, Media, News
Prescient Therapeutics on cusp of value creation, says Pitt Street Research
In valuing Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) at A11.6 cents per share in its base case and A16.3 cents in its bull case, Pitt Street Research said the ASX-listed…
Article, Media, News
Prescient Therapeutics (ASX: PTX) advances PTX-100 to pivotal Phase 2 study
PTX-100 of Prescient Therapeutics Limited (ASX: PTX) is in spotlight as it is entering a new stage. The company highlighted that PTX is on the…
Media, News
Prescient Therapeutics showcases cell therapy data at prestigious ISCT conference
Prescient Therapeutics Ltd (ASX:PTX) CEO Steven Yatomi-Clarke updates Proactive’s Elisha Newell after the biotech showcased pre-clinical CellPryme and OmniCAR data at the International Society of…
Media, News
New tumour destruction data for Prescient’s OmniCAR and CellPryme platforms
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) presented exciting new data on their OmniCAR and CellPryme cell therapy platforms at the prestigious International Society…
Media, News
Cell Therapies presentations from ISCT
Prescient was pleased to present data on our cell therapies at the prestigious International Society of Cell & Gene Therapy (ISCT) conference in Paris in…
Media, News
Major milestones Prescient Therapeutics (ASX:PTX) eyes in 2023
Clinical-stage oncology firm Prescient Therapeutics (ASX:PTX) is guided by its mission to develop novel, personalised therapies for multiple types of cancers. The company’s platform consists of targeted…